[{"address1": "Jinchuang Plaza", "address2": "Building 1, Fourth Floor 4560 Jinke Road Pudong", "city": "Shanghai", "zip": "201210", "country": "China", "phone": "86 21 6163 2588", "website": "https://www.zailaboratory.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-na\u00efve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT. The company was incorporated in 2013 and is headquartered in Shanghai, China.", "fullTimeEmployees": 2175, "maxAge": 86400, "priceHint": 2, "previousClose": 18.0, "open": 18.12, "dayLow": 17.59, "dayHigh": 18.645, "regularMarketPreviousClose": 18.0, "regularMarketOpen": 18.12, "regularMarketDayLow": 17.59, "regularMarketDayHigh": 18.645, "beta": 1.153, "forwardPE": -12.463087, "volume": 671820, "regularMarketVolume": 671820, "averageVolume": 631012, "averageVolume10days": 457010, "averageDailyVolume10Day": 457010, "bid": 18.51, "ask": 18.59, "bidSize": 200, "askSize": 200, "marketCap": 1833184000, "fiftyTwoWeekLow": 13.48, "fiftyTwoWeekHigh": 32.6, "priceToSalesTrailing12Months": 6.2980647, "fiftyDayAverage": 17.8216, "twoHundredDayAverage": 22.124926, "currency": "USD", "enterpriseValue": 17835632640, "profitMargins": -1.16448, "floatShares": 891003642, "sharesOutstanding": 98717504, "sharesShort": 3277059, "sharesShortPriorMonth": 4077667, "sharesShortPreviousMonthDate": 1713139200, "dateShortInterest": 1715731200, "sharesPercentSharesOut": 0.0332, "heldPercentInsiders": 0.02012, "heldPercentInstitutions": 0.52903, "shortRatio": 4.49, "bookValue": 7.831, "priceToBook": 2.3713446, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -338947008, "trailingEps": -3.5, "forwardEps": -1.49, "pegRatio": 0.09, "enterpriseToRevenue": 61.276, "enterpriseToEbitda": -48.47, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "ZLAB", "underlyingSymbol": "ZLAB", "shortName": "Zai Lab Limited", "longName": "Zai Lab Limited", "firstTradeDateEpochUtc": 1505914200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "8abb8ada-ed23-324a-aac0-9a720ac3e08a", "gmtOffSetMilliseconds": -14400000, "currentPrice": 18.57, "targetHighPrice": 66.0, "targetLowPrice": 25.0, "targetMeanPrice": 54.15, "targetMedianPrice": 61.0, "recommendationMean": 1.6, "recommendationKey": "buy", "numberOfAnalystOpinions": 9, "totalCash": 650780032, "totalCashPerShare": 0.656, "ebitda": -367976000, "totalDebt": 63349000, "quickRatio": 3.782, "currentRatio": 4.626, "totalRevenue": 291071008, "debtToEquity": 8.312, "revenuePerShare": 3.003, "returnOnAssets": -0.21853, "returnOnEquity": -0.38442, "freeCashflow": -225874624, "operatingCashflow": -218996992, "revenueGrowth": 0.388, "grossMargins": -0.306, "ebitdaMargins": -1.26421, "operatingMargins": -0.80677, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-06-24"}]